
Health Canada’s CBD Consultation: What You Need to Know
Health Canada is reviewing CBD as an NHP. Learn how these regulatory changes could impact the CBD industry.
One of the most significant aspects of the Cannabis Act and Regulations is the introduction of a Cannabis Drug License, which will help pave the way for companies looking to develop prescription cannabis-based medications.
This license gives companies the ability to produce and sell prescription drugs containing cannabis. Its inclusion in the Act could turn out to be especially beneficial for consumers, as while medical cannabis isn’t currently covered by insurance, the Act requires that cannabis medicines be given drug-identification numbers, which will provide them with coverage. The first step for companies with the goal of making advancements in cannabis-based drugs is obtaining this license. One important stipulation is that applicants must currently hold a Drug Establishment License (DEL) under Section C.01A.008 of the Food and Drug Regulations, which is required for the manufacturing of pharmaceuticals in general.*Full license requirements have not yet been published, but they are expected to resemble those of a Dealer’s License under the Narcotic Control Regulations.
Health Canada is reviewing CBD as an NHP. Learn how these regulatory changes could impact the CBD industry.
Australia’s Medical Cannabis Boom The Australia medical cannabis market is experiencing exponential growth, positioning itself as a leader in the global industry. With recent projections
Explore the effects of Canada’s 2025 cannabis excise tax reform on the industry and your business. Find out what it means for you today.
Understanding cannabis and hemp license reporting requirements is essential for every business to stay compliant with Health Canada’s regulations. From tracking your production to submitting
Subscribe To Our Newsletter
Get Latest Industry News and Updates